Cellulitis in compensated patients seems to behave as in a non-cirrhotic population regarding risk factors; smoking, venous insufficiency, and causative microorganisms; and has no significant impact on survival. In decompensated cirrhosis, poor liver function is the main risk factor, and gram-negative bacteria are the predominant agents. Cellulitis has a potentially poor prognosis, with mortality rates approaching 100% in decompensated patients with gram-negative cellulitis. Stratifying patients according to severity of cirrhosis is important to identify the proper empirical antibiotic and to decide the most proper means of care, either outpatient management or hospitalization.

INTRODUCTION
============

Cellulitis is a common infectious disease in cirrhosis that develops in 10.5--12.5% \[[@b1-cmh-2018-0097],[@b2-cmh-2018-0097]\]. It is responsible for significant morbidity and mortality that may require recurrent hospital admissions for early recognition and appropriate treatment \[[@b3-cmh-2018-0097]\]. Moreover, it may carry a socioeconomic burden including duration of hospitalization and high financial costs \[[@b4-cmh-2018-0097]\]. Recently, the improvement in patient management, including a high index of suspicion together with a proper use of safer prophylactic antibiotics, have significantly improved the short-term prognosis, decrease in the rate of recurrence, repeated hospitalizations and hence in-hospital mortality \[[@b5-cmh-2018-0097]\]. Several studies had discussed cellulitis in cirrhotic patients which declared that causative microorganisms, pathogenesis and prognosis were quite different from that of the general population \[[@b5-cmh-2018-0097]\].

In this study, we tried to answer some questions. First, is there a change in the causative microorganisms as an emerging of resistant or new organisms in cirrhotic patients? Second, are the microbial aspects, risk factors and clinical judgement changed with the severity of liver cirrhosis; compensated or decompensated? Third, can cellulitis affect the clinical outcomes of cirrhosis? So, we aimed to investigate the microbial aspects and the risk factors for developing cellulitis in hospitalized cirrhotic patients and their relation to the severity of cirrhosis and highlight a spot on the prognosis of cellulitis including complications and in-hospital mortality in those patients. Particularly, the shortage of data concerns these aspects of cellulitis and its sequelae in hepatitis C virus (HCV)-related liver cirrhosis.

PATIENTS AND METHODS
====================

Study design
------------

This prospective study was carried out at Assiut University Hospital; a tertiary care teaching hospital, Assiut, Egypt, from January 2018 to June 2018. The study was approved by the Local Ethics Committee of Assiut University Hospital and was conducted in accordance with the previsions of the Declaration of Helsinki. Informed consent was obtained from all the participants or from their relatives for patients with hepatic encephalopathy (HE) before enrollment.

Patients
--------

Adult patients with HCV-related cirrhosis admitted to the Department of Gastroenterology and Tropical Medicine, Al-Rajhi Liver Center, Assiut University Hospital, Assiut, Egypt between January 2018 and June 2018 were consecutively included in the study and evaluated for the presence of cellulitis. The diagnosis of cirrhosis was based on clinical, laboratory, and imaging findings \[[@b6-cmh-2018-0097],[@b7-cmh-2018-0097]\]. The severity of liver cirrhosis was assessed according to the Child--Pugh classification and model for end-stage liver disease (MELD) and MELD-Na scores \[[@b8-cmh-2018-0097]-[@b10-cmh-2018-0097]\]. Cellulitis was diagnosed by the presence of redness, warmth and swelling of the affected area \[[@b11-cmh-2018-0097]\]. According to Child--Pugh classification\[[@b8-cmh-2018-0097]\], patients were classified into a compensated (Child A) and a decompensated group (Child B and C) at diagnosis of cirrhosis.

Non-cirrhotic patients with cellulitis, cirrhotic patients with orbital cellulitis, cellulitis complicating diabetic foot ulcers, postoperative wound infection were excluded.

Methods
-------

At study entry, a thorough medical history and physical examination were taken for data collection e.g., age, sex, co-morbidities like diabetes, peripheral edema, ascites, severity of disease and cirrhosis-related complications. Laboratory investigation including liver function tests, serum creatinine, complete blood count and serum sodium were done. Doppler ultrasound was used to diagnose deep vein thrombosis in suspicious cases. Cellulitis was assessed for its site, nature, severity, and complication and specimens of aspirate or swab from the skin lesion and blood were collected before starting empirical antibiotic therapy. In-hospital mortality was assessed.

All recruited patients were treated empirically with cefotaxime (2 g i.v./12 h) or amoxicillin--clavulanic acid (1.2 g i.v./12 h) according to the decision of their physicians and shifted to adjusted antibiotic therapy according to results of antimicrobial susceptibility testing.

Microbiologic studies
---------------------

### Blood samples and culture

Samples were collected from cirrhotic patients, transported and processed in the Microbiology Laboratory Unit of Department of Clinical Pathology, Assiut University Hospital, Egypt. The infective organisms were identified by the conventional and the automated methods under universal safety precautions and standard laboratory protocols \[[@b12-cmh-2018-0097]\].

Blood samples collection: Five to 10 ml of blood was collected aseptically from each patient. Two blood culture bottles aerobic and anaerobic were incubated in BacT/Alert 3D system (BioMérieux, Marcy l'Etoile, France) according to its manufacture and the specimen was considered negative after 5 days of incubation.

Gram staining was done for the positive blood culture bottles and then inoculated onto Blood agar, MacConkey agar, chocolate media, Bile Esculin Azide agar (incubated at 37o C for 24-48 hours), two plates of saboroud's agar (one incubated at 37o C and the other at 25o C up to 14 days), all under aerobic condition. Blood agar incubated at 37o C in an anaerobic jar for 3 days, the growth was observed in the next day.

Gram staining was done for the positive growth cultures, the identification and antimicrobial susceptibility testing were performed with the VITEK 2 COMPACT-15 automated system (BioMerieux, Marcy l'Etoile, France) based on its manufacturer.

For filamentous fungal diagnosis, the visible colonies are inspected macroscopically for shape, texture and color and identified microscopically by examining the shape and the arrangement of the conidia using lactophenol cotton blue stain.

ID-GNB and AST-N223 cards were used for gram negative bacilli, ID-GP and AST-P592 cards used for gram positive cocci, IDYST and AST-Yeast07 cards for yeasts and the ID-ANC card for anaerobes. Outcomes were interpreted according to the Clinical and Laboratory Standards Institute (CLSI), 2016.

### Skin samples and culture

The skin was cleaned with an alcohol for a closed lesion and with saline for opened one, epidermal scales scraped and tacked from the active edge. Swab samples inoculated on different media for isolation of the organism then identification of gram positive or negative organisms by VITEK 2 COMPACT-15 (BioMérieux) as previous.

Statistical analysis
--------------------

Statistical analyses were conducted using SPSS for windows version 16 (IBM Corp., Armonk, NY, USA). The continuous data was expressed as means±standard deviation and was compared using Student's *t* test or Mann-Whitney *U* test and one way analysis of variance. Categorical variables were expressed as a percentage and compared using chi-squared (*χ*^2^ ) or Fisher's exact probability test. Significant factors on univariate analysis were considered for inclusion in multiple regression analysis. For all analyses, *P*-value\<0.05 was considered statistically significant.

RESULTS
=======

Characteristics of the studied patients
---------------------------------------

A total of 620 patients with HCV-related liver cirrhosis admitted to Department of Gastroenterology and Tropical Medicine, Al-Rajhi Liver Center, Assiut University Hospital, Assiut, Egypt, between January 2018 and June 2018 were enrolled in the study. Cellulitis was diagnosed in 12.4% (77/620) of patients (48 males and 29 females with mean age of 57.7±7.5 years). The majority of patients with cellulitis had decompensated cirrhosis "Child classes B and C (52/77, 67.5%)", and the remaining 25 patients had compensated cirrhosis "Child class A (32.5%)". Pain at site of cellulitis was a most common symptom (90.9%). The most common site of cellulitis was in the lower extremities which were found in 74 cases (96.1%), while the upper extremities were less frequently involved (3.9%). More than one area of cellulitis was involved in seven cases (9.1%) while nine (11.7%) cases had abscesses. In addition, six (7.8%) cases were complicated with gangrene and surgical debridement was required in four of them, while one case had hemorrhagic bullae.

In patients with compensated cirrhosis, smoking and venous insufficiency were significantly higher compared to patients with decompensated cirrhosis and those without cellulitis. Exposure to trauma was higher in compensated patients but without statistical significance. On the other hand, about 28% (7/25) of compensated patients with cellulitis did not have obvious lesions on the body surface that allow microbial invasion. However, ascites and peripheral edema were the commonest predisposing factors for cellulitis in patients with decompensated cirrhosis. In addition, patients with decompensated cirrhosis had significantly higher serum bilirubin and lower serum albumin compared to those without decompensation and cellulitis. In addition, frequencies of local complications, recurrence and septic shock were higher in patients with decompensated cirrhosis but without statistical significance ([Table 1](#t1-cmh-2018-0097){ref-type="table"}).

Further clinical and laboratory data of the studied patients and their subgroups at and during admission were summarized in [Table 1](#t1-cmh-2018-0097){ref-type="table"}.

Of 77 cirrhotic patients with cellulitis, 28 (36.4%) cases were confirmed bacteriologically either from blood or from skin aspirates (14 from blood, 7 from skin, and 7 from both). These cases were 13 females and 15 males, with a mean age of 59.7±10.8 years. The remaining 49 patients (16 females and 33 males with a mean age of 58.1±10.2 years) had negative cultures. Gram positive bacteria were isolated from 19 specimens (10 from blood and 9 from skin), Gram negative bacteria were isolated from 24 specimens (19 from blood and 5 from skin) and three fungi (2 from blood and 1 from skin). None of the patients had anaerobic bacterial infection. The most frequent gram positive bacteria causing cellulitis was *Staphylococcus* species (14/19, 73.7%) with *Staphylococcus aureus* being the commonest (9/19, 47.4%). The most common gram negative bacteria was *Escherichia coli* (11/24, 45.8%). The details of microbial infections among cirrhotic patients with cellulitis were shown in [Table 2](#t2-cmh-2018-0097){ref-type="table"} where isolated organisms were gram positive in compensated cirrhosis while gram negative bacteria were causative organisms of cellulitis in most cases of decompensated cirrhosis. Fungi were isolated in decompensated patients.

Concerning antibiotic therapy in cirrhotic patients with cellulitis, the median duration of antibiotic therapy was 7 (3--25) days. All recruited patients received empirical antibiotics (70 patients \[90.9%\] received cefotaxime and 7 \[9.1%\] received amoxicillin-- clavulanic acid therapy) then 19 cases of them received adjusted antibiotic therapy according to results of antimicrobial susceptibility testing.

Twenty-one patients with cellulitis (27.3%) died during hospitalization. We found that all non-survivors (11 cases) with positive cultures were of gram negative cellulitis per se or combined infection with gram positive bacteria. Details of characteristics of bacteriologically-proved cellulitis, risk factors and treatment among the deceased cirrhotic patients were summarized in [Table 3](#t3-cmh-2018-0097){ref-type="table"}.

Determination of risk factors for in-hospital mortality in cirrhotic patients with cellulitis
---------------------------------------------------------------------------------------------

Univariate analysis showed that lower limb (LL) edema, serum creatinine, sodium, International Normalized Ratio (INR), Child-Pugh, MELD and MELD-Na scores were significantly associated with in-hospital mortality in cirrhotic patients with cellulitis. In addition, prolonged hospital stay and complications registered during hospitalization; recurrent, locally complicated cellulitis and septic shock were significantly higher in deceased cases than in survivors ([Table 4](#t4-cmh-2018-0097){ref-type="table"}).

In the multivariate analysis, we included the Child-Pugh and MELD-Na scores in place of INR, MELD, serum creatinine and sodium (which were the components of these scores) for prediction of in-hospital mortality in cirrhotic patients with cellulitis. As a result, prolonged hospital stay, recurrent, locally complicated cellulitis, septic shock and higher MELD-Na score were associated with in-hospital mortality ([Table 5](#t5-cmh-2018-0097){ref-type="table"}).

DISCUSSION
==========

The current study justified to answer several questions on risk factors, microorganisms and prognosis of cellulitis in patients with compensated and decompensated cirrhosis. Infections are common complications in cirrhosis where, patients with decompensated cirrhosis were more prone to infection than compensated cirrhosis. Among cirrhotic patients cellulitis was found in 12.4% which was within the range of the earlier estimates \[[@b1-cmh-2018-0097],[@b2-cmh-2018-0097]\]. This study corroborates differences between compensated and decompensated cirrhosis as regarding risk factors, microbial aspects and sequelae of cellulitis.

In this study, similar to general population \[[@b13-cmh-2018-0097]-[@b15-cmh-2018-0097]\], cellulitis in compensated cirrhosis occurred independently in the absence of ascites and peripheral edema, where smoking, venous insufficiency and trauma may be the predisposing factors. In addition, it may occur due to disruption of mechanical defenses following a trivial injury as itching. In line with previous studies \[[@b16-cmh-2018-0097],[@b17-cmh-2018-0097]\], we found that no obvious local lesions allowing bacterial invasion could be detected in 28% of those patients.

On the other hand, peripheral edema, ascites, hyperbilirubineamia, and hypoalbumineamia were associated with cellulitis in patients with decompensated cirrhosis. Several studies reported that low serum albumin (\<2.5 g/dL) and high serum bilirubin (\>3 mg/dL) were significantly associated with the development of cellulitis \[[@b2-cmh-2018-0097],[@b5-cmh-2018-0097]\]. Poor liver function in decompensated patients may increase the risk of developing infection which may be due to defect in bactericidal activity of immunoglobulin, decreased opsonic and neutrophil functions, complement deficiency, or reduced number of Kupffer cells and fibronectin levels \[[@b18-cmh-2018-0097],[@b19-cmh-2018-0097]\].

Compatible with previous studies \[[@b2-cmh-2018-0097],[@b16-cmh-2018-0097],[@b17-cmh-2018-0097],[@b20-cmh-2018-0097]\], peripheral edema was significantly associated with cellulitis in decompensated patients that can be explained by seeding of the bacteria in the edematous soft tissue via the bloodstream through the intestinal portal route. Mohan et al. \[[@b2-cmh-2018-0097]\], reported that cirrhotic patients usually have chronic LL edema serving as the origin of infections.

As in non-cirrhotic patients' series \[[@b21-cmh-2018-0097],[@b22-cmh-2018-0097]\], the current work reported similarly that the main etiological organisms were gram positive bacteria in compensated patients, where, *Staphylococcus aureus* and *Streptococcus pyogenes*, were the most frequent causative organisms. However, gram negative bacteria as *E. coli* and *Klebsiella pneumoniae* were the most predominant organisms in decompensated patients \[[@b2-cmh-2018-0097],[@b23-cmh-2018-0097]\].

Gram negative cellulitis were seen in decompensated cirrhosis possibly due to increased bacterial translocation and intestinal overgrowth which establishing gram negative bacteremia that result either in primary septicemia or localized infections like cellulitis \[[@b5-cmh-2018-0097],[@b24-cmh-2018-0097]\]. In addition, defective bactericidal function of serum immunoglobulin M for *E. coli* may be accused \[[@b19-cmh-2018-0097]\]. However, the increased risk of colonization by methicillin-resistant *Staphylococcus aureus* and *Pseudomonas* may be due to recurrent hospitalization or empirical widespread use of antibiotics in those patients \[[@b4-cmh-2018-0097]\].

It was the first time to report fungal infection in decompensated patients with cellulitis; *Candida albicans* (one case) and *Aspergillus niger* (two cases) in skin and blood cultures, respectively. This finding may reflect that fungal pathogens are becoming increasingly common in those immune-compromised patients with different types of infections. *Candida* infection could be attributed to translocation of supercolonized fungi secondary to changes in the intestinal bacterial to the extraluminal areas or direct percutaneous inoculation of fungi or preceding recognized pulmonary disease as in *Aspergillus* infection \[[@b25-cmh-2018-0097],[@b26-cmh-2018-0097]\].

The current study reported that in-hospital mortality rate among cirrhotic patients with cellulitis was (27.3%) that much higher than that shown in previous studies (19--22%) \[[@b2-cmh-2018-0097],[@b24-cmh-2018-0097]\]. Moreover, this study failed to show any significant impact of cellulitis on survival of compensated patients. Earlier studies suggested that although infections frequently develop in compensated patients, they seem to independently affect survival predominantly in those diagnosed with decompensated disease \[[@b27-cmh-2018-0097],[@b28-cmh-2018-0097]\]. So, it seems that advanced hepatic cirrhosis, its related complications and aggressive cellulitis sequelae that may progress to septic shock and death have major prognostic importance in this group of patients.

We documented that all deceased patients with bacteriologically proved cellulitis were of gram negative cellulitis per se or in combination with gram positive that was compatible with Horowitz et al. \[[@b23-cmh-2018-0097]\], who supported the early diagnosis and treatment of gram negative cellulitis to avoid serious consequences. Similar to Carratalà et al. \[[@b29-cmh-2018-0097]\], we revealed that all patients with *Pseudomonas aeruginosa* cellulitis developed septic shock and died. So, Carratalà and colleagues suggested that the initial empirical antibiotic therapy for patients with cellulitis presenting with shock should include anti-pseudomonal agents \[[@b29-cmh-2018-0097]\].

In this study, prolonged hospital stay, higher MELD-Na score, complicated cellulitis, septic shock and recurrence of cellulitis were risk factors of in-hospital mortality of cirrhotic patients with cellulitis. Carratalà et al. \[[@b29-cmh-2018-0097]\], reported that shock at presentation was related to in-hospital mortality in patients with cellulitis. This is strongly showed the need for the prompt institution of adequate empirical antibiotic therapy. Prolonged hospital stay may partly be explained by the presence of more co-morbidities leading to higher nosocomial infection and hence death \[[@b30-cmh-2018-0097]\]. In addition, prolonged hospitalization was associated with hypoalbuminemia and renal insufficiency that were independent predictors for inhospital mortality in cirrhotic patients \[[@b29-cmh-2018-0097]\].

This study has certain strengths and limitations. This study explored the difference in risk factors, causative microorganisms and prognosis of cellulitis in compensated and decompensated cirrhosis. This is one of the very few studies which investigated fungal infection as infective organisms for cellulitis and looked into complications and factors associated with in-hospital morality in cirrhotic patients with cellulitis. In addition, we mainly assessed cellulitis in patients with HCV-related liver disease; the most common cause of cirrhosis in Egypt. Unlike earlier studies, cellulitis had been assessed in cirrhotic patients with different etiologies.

On the other hand, there were several limitations of this study. Our study was a single-center study that occurred in Assiut University Hospital; a tertiary care center, where less severe stage of cirrhosis is less possible to be admitted so, the sample may not exactly represent the general population of cirrhotic patients. The high percentage of empirical use of antimicrobials in cirrhotic patients for different reasons e.g., HE, bleeding varices or spontaneous bacterial peritonitis prophylaxis may underestimate the results of cultures. Also, we could not investigate cases of recurrent cellulitis as their lower frequency (eight cases). Therefore, further multicenter prospective studies are required to identify risk factors of recurrent cellulitis in cirrhotic patients and to investigate antibiotic prophylaxis for cellulitis in those patients who have high-risk factors.

In conclusion, cellulitis in patients with compensated cirrhosis is different from that of the decompensated patients regarding microorganisms, pathogenesis and prognosis. Cellulitis has an impact on the course of decompensated cirrhosis with a potentially poor prognosis in whom a septic shock develops with mortality rates approaching 100% in gram negative cellulitis. Stratifying patients according to the severity of liver disease is important to identify the chosen empirical antibiotic and to decide the most proper means of care; either outpatient management or hospitalization. Prolonged hospitalization, higher MELD-Na score, septic shock, recurrent and complicated cellulitis were predictors of inhospital mortality. Early diagnosis and optimal treatment of cellulitis is a crucial step in the management of those high risk patients.
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CLSI

:   Clinical and Laboratory Standards Institute

*E. coli*

:   *Escherichia coli*

HE

:   hepatic encephalopathy

INR

:   international normalized ratio

LL

:   lower limb

MELD

:   model for end-stage liver disease

###### 

Characteristics and risk factors of cellulitis in patients with hepatitis C virus-related cirrhosis (compensated and decompensated)

                                                                        Compensated LC patients with cellulitis (n=25)   Decompensated LC patients with cellulitis (n=52)   LC patients with no cellulitis^[\*](#tfn1-cmh-2018-0097){ref-type="table-fn"}^ (n=543)   *P*-value
  --------------------------------------------------------------------- ------------------------------------------------ -------------------------------------------------- ---------------------------------------------------------------------------------------- -----------
  Age (years)                                                           56.8±4.3                                         58.6±10.6                                          57.5±13.3                                                                                0.852
  Sex (male/female)                                                     15/10 (60/40)                                    33/19 (63.5/36.5)                                  336/207 (61.9/38.1)                                                                      0.827
  Smoking                                                               12 (48)                                          8 (15.4)                                           43 (7.9)                                                                                 0.047
  DM                                                                    6 (24)                                           14 (26.9)                                          206 (37.9)                                                                               0.490
  Fever                                                                 13 (52)                                          32 (61.5)                                          277 (51)                                                                                 0.259
  Pain at the site of cellulitis                                        22 (88)                                          48 (92.3)                                          \-                                                                                       0.773
  Venous insufficiency^[†](#tfn2-cmh-2018-0097){ref-type="table-fn"}^   13 (52)                                          12 (23.1)                                          67 (12.3)                                                                                0.032
  Trauma                                                                5 (20)                                           6 (11.5)                                           51 (9.4)                                                                                 0.439
  No local risk detected                                                7 (28)                                           4 (7.7)                                            \-                                                                                       0.041
  Lower limb edema                                                      0                                                39 (75)                                            294 (54.1)                                                                               0.002
  Ascites                                                               0                                                48 (92.3)                                          381 (70.2)                                                                               0.042
  Site of cellulitis^[‡](#tfn3-cmh-2018-0097){ref-type="table-fn"}^                                                                                                         \-                                                                                       
   Lower extremities                                                    25 (100)                                         49 (92.2)                                                                                                                                   0.067
   Upper extremities                                                    0                                                3 (5.8)                                                                                                                                     
   Anterior abdominal wall                                              0                                                14 (26.2)                                                                                                                                   
  Gastrointestinal bleeding                                             0                                                4 (7.7)                                            65 (12)                                                                                  0.492
  Spontaneous bacterial peritonitis                                     0                                                11 (21.2)                                          98 (18)                                                                                  0.556
  Hepatic encephalopathy                                                0                                                19 (36.5)                                          207 (38.1)                                                                               0.287
  Hepatocellular carcinoma                                              5 (20)                                           8 (15.4)                                           130 (23.9)                                                                               0.432
  Serum albumin (g/dL)                                                  3.7±0.4                                          2.1±0.5                                            2.6±0.7                                                                                  0.002
  Serum bilirubin (mg/dL) (median, range)                               0.8 (0.4--1.3)                                   2.9 (0.2--22.2)                                    2.3 (0.3--23.2)                                                                          0.045
  AST (U/L) (median, range)                                             21.5 (4--276)                                    61 (10--427)                                       52.5 (13--309)                                                                           0.864
  ALT (U/L) (median, range)                                             38.5 (4--145)                                    34 (9--220)                                        32 (5--558)                                                                              0.563
  INR                                                                   1.2±0.1                                          1.8±0.8                                            1.6±0.5                                                                                  0.060
  Serum creatinine (µmol/L) (median, range)                             69.5 (55--93)                                    101 (38--559)                                      103.5 (22--627)                                                                          0.367
  Serum sodium (mmol/L)                                                 137±3.4                                          133±6                                              134±6.5                                                                                  0.174
  Leukocytic count (×10^9^/L)                                           8.4±2.5                                          9.5±3.8                                            7.4±2.3                                                                                  0.409
  Hemoglobin (gm/dL)                                                    10.4±1.8                                         10.1±2.2                                           9.1±2.4                                                                                  0.770
  Platelet count (×10^9^/L)                                             138.5±42                                         109.7±50.2                                         132.1±78.7                                                                               0.161
  MELD score                                                            12±1.8                                           23±8.5                                             20.5±7.5                                                                                 0.015
  MELD-Na score                                                         12.8±2.8                                         28.6±12.9                                          25.3±10.2                                                                                0.049
  Local complications                                                                                                                                                       \-                                                                                       
   Abscesses                                                            2 (8)                                            7 (12.5)                                                                                                                                    0.651
   Gangrene                                                             1 (4)                                            5 (9.6)                                                                                                                                     
   Hemorrhagic bullae                                                   0                                                1 (1.9)                                                                                                                                     
  Recurrence                                                            1 (4)                                            7 (12.5)                                           \-                                                                                       0.510
  Septic shock                                                          0                                                6 (11.5)                                           \-                                                                                       0.597
  In-hospital mortality                                                 0                                                21 (40.4)                                          184 (33.9)                                                                               0.354

Values are presented as mean±standard deviation or n (%) unless otherwise indicated. P -value \<0.05 means significant.

LC, liver cirrhosis; DM, diabetes mellitus; AST, aspartate transaminase; ALT, alanine transaminase; INR, international normalized ratio; MELD, model for endstage liver disease.

No cellulitis group included compensated and decompensated cirrhotic patients without cellulitis.

More than one area of cellulitis was seen in seven cases (leg and anterior abdominal wall cellulitis).

Venous insufficiency was diagnosed by doppler ultrasonography.

###### 

Frequency of microorganisms in 23 cirrhotic patients with cellulitis (in skin and blood cultures)

  Organisms                                     Compensated cirrhosis   Decompensated cirrhosis
  --------------------------------------------- ----------------------- -------------------------
  Gram positive bacteria (skin/blood culture)                           
   *Streptococcus pyogenes*                     3 (2/1)                 2 (0/2)
   *Staphylococcus species*                     4 (3/1)                 10 (4/6)
    MRCNS                                       1 (1/0)                 1 (0/1)
    MSSA                                        \-                      2 (1/1)
    MRSA                                        2 (1/1)                 5 (2/3)
    *Staphylococcus coagulase*                  \-                      1 (1/0)
    *Staphylococcus hominis*                    1 (1/0)                 1(0/1)
  Gram negative bacteria (skin/blood culture)                           
   *Escherichia coli*                           0                       11 (2/9)
   *Klebsiella pneumoniae*                      0                       10 (3/7)
   *Pseudomonas aeruginosa*                     0                       3 (0/3)
  Fungi (skin/blood culture)                                            
   *Candida albicans*                           0                       1 (1/0)
   *Aspergillus niger*                          0                       2 (0/2)

MRCNS, methicillin-resistant coagulase-negative *Staphylococci*; MSSA, methicillin-sensitive *Staphylococcus aureus*; MRSA, methicillin-resistant *Staphylococcus aureus*.

###### 

Detailed characteristics of bacteriologically-proven cellulitis in deceased cirrhotic patients

  No.   Age Sex   Cellulitis                                                                Host factors                             CP   MELD   Skin/Blood culture                    Treatment
  ----- --------- ------------------------------------------------------------------------- ---------------------------------------- ---- ------ ------------------------------------- -------------------------
  1     82/F      Recurrent bilateral LL cellulitis: severe, not oozing                     DM, fever, HE, septic shock              11   28     *E. coli/P. aeruginosa*               Empirical
  2     78/F      Bilateral LL cellulitis: severe, not oozing                               HE, intractable ascites                  11   25     -/*K. pneumoniae*                     Empirical
  3     65/M      Bilateral LL cellulitis: pyogenic, severe, oozing                         DM, HTN, fever, HRS                      8    27     *Staph. coagulase/E. coli*            Empirical
  4     57/M      Left LL cellulitis: severe, not oozing. echymosis, bullae below big toe   HE, fever, septic shock                  13   29     -/*P. aeruginosa, E. coli*            Empirical then adjusted
  5     55/M      Anterior abdominal wall: severe, oozing, ulceration, abscess              DM, intractable ascites, SBP             13   20     -/MRCNS, *K. pneumoniae*              Empirical
  6     55/M      Recurrent right LL cellulitis: severe, not oozing                         HCC, HRS, intractable ascites            15   42     *K. pneumoniae*/MRSA, *E. coli*       Empirical
  7     55/F      Anterior abdominal wall: severe, oozing. gangrene                         DM, HTN, HE                              9    21     *E. coli/K. pneumoniae*               Empirical then adjusted
  8     55/F      Left LL cellulitis: severe, oozing, gangrene                              DM, HCC, fever, septic shock             11   31     MRSA,*K. pneumoniae/E. coli*          Empirical
  9     52/F      Recurrent bilateral LL cellulitis: severe, not oozing                     Fever, HRS, HE                           14   40     -/*K. pneumoniae*                     Empirical
  10    45/M      Anterior abdominal wall: severe, oozing, abscess                          Intractable ascites, SBP, septic shock   14   29     -/*Strept. pyogenes, P. aeruginosa*   Empirical then adjusted
  11    44/M      Right LL cellulitis: severe, oozing                                       Intractable ascites, HRS                 10   22     *K. pneumoniae*/-                     Empirical

CP, Child--Pugh classification; MELD, model for end-stage liver disease; F, female; LL, lower limb; DM, diabetes mellitus; HE, hepatic encephalopathy; *E. coli, Escherichia coli; P ., Pseudomonas; K. , Klebsiella*; M, male; HTN, hypertension; HRS, hepatorenal syndrome; *Staph. , Staphylococcus*; SBP, spontaneous bacterial peritonitis; MRCNS, methicillin-resistant coagulase-negative *staphylococci*; HCC, hepatocellular carcinoma; MRSA, methicillin-resistant *Staphylococcus aureus*; *Strept., Streptococcus*.

###### 

Demographic and clinical characteristics of cirrhotic patients with cellulitis (survivors and non-survivors)

                                                                                                       Survivors (n=56)         Non-survivors (n=21)   *P*-value
  ---------------------------------------------------------------------------------------------------- ------------------------ ---------------------- -----------
  Age (years)                                                                                          58.9±10                  57.4±11.4              0.605
  Sex (male/female)                                                                                    35/21 (62.5/37.5)        13/8 (61.9/38.1)       0.910
  Smoking                                                                                              15 (26.8)                5 (23.8)               0.633
  Diabetes mellitus                                                                                    16 (28.6)                4 (19)                 0.542
  Hospital stay (days) (median, range)                                                                 7 (3--20)                13 (2--25)             0.029
  Fever                                                                                                34 (60.7)                11 (52.4)              0.718
  Pain at the site of cellulitis                                                                       51 (91.1)                19 (99.5)              0.859
  Traumatic wounds                                                                                     8 (14.3)                 3 (14.3)               0.508
  Venous insufficiency                                                                                 18 (32.1)                7 (33.3)               0.901
  LL edema                                                                                             21 (37.5)                18 (85.7)              0.037
  Ascites                                                                                              32 (57.1)                16 (76.2)              0.155
  Site of cellulitis^[\*](#tfn4-cmh-2018-0097){ref-type="table-fn"}^ (UL/LL/anterior abdominal wall)   3/55/9 (5.4/98.2/16.1)   0/19/5 (0/90.5/23.8)   0.422
  Gastrointestinal tract bleeding                                                                      4 (7.1)                  0                      0.201
  Spontaneous bacterial peritonitis                                                                    7 (12.5)                 4 (19)                 0.678
  Hepatic encephalopathy                                                                               12 (21.4)                7 (33.3)               0.276
  Hepatocellular carcinoma                                                                             8 (14.3)                 5 (23.8)               0.231
  Complicated cellulitis                                                                               7 (12.5)                 9 (42.9)               \<0.001
  Septic shock                                                                                         0                        6 (28.6)               0.023
  Recurrent cellulitis                                                                                 2 (3.6)                  6 (28.6)               0.025
  Treatment (empirical/empirical then adjusted)                                                        42/14 (75/25)            16/5 (76.2/23.8)       0.780
  Serum albumin (g/dL)                                                                                 21.1±5.2                 21.6±4.2               0.733
  Serum bilirubin (mg/dL) (median, range)                                                              2.5 (0.4--14.4)          3.4 (0.2--22.2)        0.101
  INR                                                                                                  1.6±0.4                  2.3±0.3                0.034
  Serum creatinine (µmol/L) (median, range)                                                            87 (42--347)             176 (38--559)          0.047
  Serum sodium (mmol/L)                                                                                133.4±5.3                130.2±7.1              0.046
  Leukocytic count (×10^9^/L)                                                                          8.1±3.8                  13±5.8                 0.067
  Child-Pugh score                                                                                     10±2                     11.3±2.4               0.031
  MELD score                                                                                           19.8±7                   28.9±9.4               \<0.001
  MELD-Na score                                                                                        22.9±9.2                 38.2±10.5              \<0.001

Values are presented as mean±standard deviation or n (%) unless otherwise indicated. *P*-value \<0.05 means significant.

UL, upper limb; LL, lower limb; INR, international normalized ratio; MELD, model for end-stage liver disease.

More than one area of cellulitis was seen in seven cases (leg and anterior abdominal wall cellulitis).

###### 

Predictors of in-hospital mortality in cirrhotic patients with cellulitis

                                   Odds ratio (95% CI)   *P*-value
  -------------------------------- --------------------- -----------
  Hospital stay (days)             1.27 (1.07--1.49)     0.005
  Lower limb edema                 1.77 (0.29--10.41)    0.537
  Locally complicated cellulitis   21.56 (3.31--40.42)   0.001
  Recurrent cellulitis             17.35 (2.60--25.71)   0.003
  Septic shock                     5.41 (0.88--33.36)    0.032
  Child-Pugh score                 0.66 (0.36--1.22)     0.185
  MELD-Na score                    1.33 (1.12--1.58)     0.001

*P*-value\<0.05 means significant.

CI, confidence interval; MELD, model for end-stage liver disease.
